Consumer genetics firm 23andMe has partnered with clinical trial technology company TrialSpark to offer a new patient-centric, data-driven solution.
The new offering is intended to enable quick site selection, activation, patient recruitment and trial execution. It is based on 23andMe’s crowdsourced research platform and consenting customers’ database.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The solution is backed by the distributed site network and trial services of TrialSpark.
23andMe’s portfolio includes direct-to-consumer Genetic Health Risk reports. The company’s research platform can be used by customers for participation in research and surveys on non-genetic information.
The platform is expected to support clinical trial recruitment by selecting appropriate patients for the right trials. 23andMe then contacts right, consented research participants for personalised enrolment.
The company can also use its re-contactable database to improve patient engagement.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData23andMe business development vice-president Emily Drabant Conley said: “23andMe’s unique model solves for the biggest challenge in clinical trials, patient recruitment.
“It’s game-changing, because it is built around engaged customers who consent to participate in research, and it allows 23andMe to quickly find the right patients with the right conditions for clinical trials. Now with TrialSpark, we are taking this one step further by enabling our customers access to clinical trial sites within their community.”
TrialSpark collaborates with doctors to generate clinical trial sites in their existing practices and provides equipment, software and personnel support.
The company works towards increased trial access to patients, enrolment and retention rates, and diversity of participants. Its operating model also enables the collection of data and endpoints using wearable technology, digital therapeutics and at-home 23andMe genetic testing.
TrialSpark CEO and co-founder Benjamine Liu said: “This collaboration with 23andMe is a major step toward redefining modern clinical trials and accelerating the pace of medical discoveries.
“By using technology and a patient-first approach, we can run clinical trials with faster timelines and with operational consistency, ultimately bringing therapies to patients faster.”
The partners are currently inviting clinical trial proposals from sponsors across various therapeutic areas, including neurology, rare diseases, pulmonology and dermatology.
